Acyclovir bioavailability in patients with acute myelogenous leukemia treated with daunorubicin and cytarabine.
Sitar
Daniel S
DS
Section of Clinical PharmacologyDepartment of Internal Medicine, Faculty of Medicine, University of Manitoba, A220-753 McDermot Avenue, Winnipeg, Manitoba R3E 0T6, Canada.sitar@cc.umanitoba.ca.
Aoki
Fred Y
FY
Bow
Eric J
EJ
D000212:Acyclovir / Q000493:pharmacokinetics*; D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000493:pharmacokinetics*; D001682:Biological Availability; D018592:Cross-Over Studies; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000998:Antiviral Agents; D003561:Cytarabine; D000212:Acyclovir; D003630:Daunorubicin